| 000 | 01877 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515152823.0 | ||
| 264 | 0 | _c20090327 | |
| 008 | 200903s 0 0 eng d | ||
| 022 | _a1464-3391 | ||
| 024 | 7 |
_a10.1016/j.bmc.2008.11.049 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDuncton, Matthew A J | |
| 245 | 0 | 0 |
_aArylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry _cJan 2009 |
||
| 300 |
_a731-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aIsoquinolines _xchemical synthesis |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred Strains |
| 650 | 0 | 4 |
_aPhthalazines _xadministration & dosage |
| 650 | 0 | 4 | _aPiperidines |
| 650 | 0 | 4 | _aQuinazolines |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor Receptor-1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor Receptor-2 _xantagonists & inhibitors |
| 700 | 1 | _aPiatnitski Chekler, Eugene L | |
| 700 | 1 | _aKatoch-Rouse, Reeti | |
| 700 | 1 | _aSherman, Dan | |
| 700 | 1 | _aWong, Wai C | |
| 700 | 1 | _aSmith, Leon M | |
| 700 | 1 | _aKawakami, Joel K | |
| 700 | 1 | _aKiselyov, Alexander S | |
| 700 | 1 | _aMilligan, Daniel L | |
| 700 | 1 | _aBalagtas, Chris | |
| 700 | 1 | _aHadari, Yaron R | |
| 700 | 1 | _aWang, Ying | |
| 700 | 1 | _aPatel, Sheetal N | |
| 700 | 1 | _aRolster, Robin L | |
| 700 | 1 | _aTonra, James R | |
| 700 | 1 | _aSurguladze, David | |
| 700 | 1 | _aMitelman, Stan | |
| 700 | 1 | _aKussie, Paul | |
| 700 | 1 | _aBohlen, Peter | |
| 700 | 1 | _aDoody, Jacqueline F | |
| 773 | 0 |
_tBioorganic & medicinal chemistry _gvol. 17 _gno. 2 _gp. 731-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmc.2008.11.049 _zAvailable from publisher's website |
| 999 |
_c18551998 _d18551998 |
||